Loading...

MAIA MAIA BIOTECHNOLOGY INC Company Mergers 8-K Filing

M BT

M

MAIA BIOTECHNOLOGY INC

(MAIA)

2026 8-K

Survival Report

Research Presentation

Stock Offering Announcement

Shareholder Update

Clinical Milestones Update

Presentation Materials

Private Placement Details

Company Developments

Market Entry Announcement

Clinical Program Update

Press Release Issued

Conference Presentations

Conference Presentation

Clinical Trial Updates

Securities Agreement

New Digital Strategy

Funding Announcement

NIH Grant Award

Warrant Exercise Agreement

Positive Trial Results

Clinical Trial Results

Market Expansion

Clinical Trials

Clinical Trials

Asset Acquisitions

Equity Offerings

New Product Launches

Regulatory Compliance

Equity Offerings

Share Increase Proposal

Business Presentation

Shareholder Update

Clinical Trial Update

Stock Offering Update

Business Presentation

Private Placement

Private Placement

Executive Changes

Stock Offering Increase

FDA Designation

Private Placement

Clinical Trial Update

Presentation Announcement

Private Placement

Investor Presentation

Treatment Updates from Phas...

Presentation and Summary Re...

Clinical Trial Results

Increase in Offering Price

Regulation FD Disclosure

Private Placement

Salary Increase

Private Placement

Increase in Offering Price

Private Placement

Appointment to Scientific A...

Completion of Enrollment fo...

Agreement to Sell Shares

Clinical Trial Update

Clinical Trial Update

Equity Offering

Warrant Issuance

Termination of Sales Agreem...

FDA Orphan Drug Designation...

Earnings Report

Clinical Trial Results

Share Repurchase Program

Sales Agreement

Earnings Report

Clinical Trial Update

Annual Meeting of Stockholders

Earnings Report

Public Offering

Earnings Report

Management Changes

Clinical Trial Announcement

Restatement of Financial St...

External Links:

On February 24, 2026, MAIA Biotechnology, Inc. released its 2026 Letter to Shareholders, highlighting its development pipeline and announcing progress in the Phase 3 trials, which targets a $50 billion market in immunotherapy.

AI Assistant

MAIA BIOTECHNOLOGY INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.